ArticleInfection and immunity2022
Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections.
Article in Infection and immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Loss of O-antigen due toScience advances · 2026Article
- Global survey of extraintestinal pathogenic Escherichia coli identifies stable serogroup-virulence-resistance linkages.Genome medicine · 2026Article
- Research progress on multivalent genetically engineered vaccines against enterotoxigenicFrontiers in immunology · 2026Review
- The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune Responses.Vaccines · 2025Review
- Next-generation mRNA vaccines eliciting robust protection against multidrug-resistant Enterobacteriaceae.NPJ vaccines · 2025Article
- Structural and Serological Characterization of Yet Another New O Antigen, O86, inInternational journal of molecular sciences · 2024Article
- A cynomolgus monkeyInfection and immunity · 2024Article
- Preclinical validation of anMicrobiology spectrum · 2024Article
- Progress toward a vaccine for extraintestinal pathogenicInfection and immunity · 2024Article
- A human urothelial microtissue model reveals shared colonization and survival strategies between uropathogens and commensals.Science advances · 2023Article
- The clinical, genomic, and microbiological profile of invasive multi-drug resistantMicrobial genomics · 2023Article
- Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.Microbiology and molecular biology reviews : MMBR · 2023Review
- Broad protective vaccination against systemic Escherichia coli with autotransporter antigens.PLoS pathogens · 2023Article
- Semisynthetic Glycoconjugate Vaccine Candidates againstJACS Au · 2022Article
- Vaccines against extraintestinal pathogenicGut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multivalent O-antigen polysaccharide glycoconjugate vaccines are under development to prevent invasive infections caused by pathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.